TITLE:
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma

CONDITION:
Kidney Neoplasms

INTERVENTION:
Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor

SUMMARY:

      The primary purpose of this protocol is to determine the activity of AG 013736 in patients
      with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Histologically documented RCC with metastases.

          -  Failure of 1 prior cytokine-based therapy (interleukin-2 and/or interferon) due to
             disease progression or unacceptable treatment-related toxicity

        Exclusion Criteria:

          -  Any prior systemic treatment for Renal Cell Carcinoma [RCC] other than 1 prior
             cytokine-based treatment regimen. Cytokine-based regimens containing thalidomide or
             an anti-angiogenesis agent are not allowed.

          -  Inability to take oral medication
      
